相关实验视频

Updated: Jun 15, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

关键脂蛋白受体向乙化 - - 在小鼠模型中有效对抗帕金森病

Zemin Ou¹, Yun You¹, Hong Yi¹

¹Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.

International journal of nanomedicine

|August 26, 2024

概括

这项研究开发了angiopep-2修饰脂质体 (ECH@ANG-Lip),以改善帕金森病 (PD) 的 Echinacoside (ECH) 输送. 在PD模型中,ECH@ANG-Lip增强了大脑吸收和神经保护.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
生物技术是生物技术.

背景情况:

帕金森病 (PD) 涉及多巴胺能神经元损失,没有有效的治疗方法.
乙化 (ECH) 显示神经保护,但由于血脑屏障 (BBB) 而面临生物可用性挑战.

研究的目的:

开发和评估血管-2-修饰脂质体 (ECH@ANG-Lip) 以提高脑部输送ECH.
在帕金森病模型中评估ECH@ANG-Lip的神经保护功效.

主要方法:

合成和特征化了PEGylated ECH脂质体 (ECH@Lip) 和angiopep-2修饰的脂质体 (ECH@ANG-Lip).
优化了angiopep-2密度和评估脑向在体外 (transwell BBB模型) 和体内 (成像,LC-MS).
在1-甲基-4--1,2,3,6-四胺 (MPTP) 诱导的PD模型中评估神经保护作用.

主要成果:

ECH@ANG-Lip表现出明显更高的全脑吸收比ECH@Lip和自由ECH.
ECH@ANG-Lip有效地缓解了MPTP诱导的行为缺陷,氧化应激和多巴胺基神经元损失.
与对照组相比,该配方在减少多巴胺耗尽方面表现出更高的有效性.

结论:

开发的ECH@ANG-Lip配方显著提高了ECH的生物可用性和大脑中的神经保护作用.
作为帕金森病治疗的治疗策略,ECH@ANG-Lip显示出相当大的潜力.

关键词:

帕金森病是帕金森氏症的一种疾病.安吉奥佩普-2 的使用.大脑传递大脑传递这是一种 echinacoside.脂质体是一种脂质体.纳米医药是一种纳米医药.

更多相关视频

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

相关概念视频

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Lysosomal Hydrolases

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...